drugset / Trial / NCT05576038
Tryptophan for Impaired AhR Signaling in Celiac Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a prospective, randomized, double-blind, placebo-controlled exploratory trial to evaluate the effect of L-tryptophan supplementation on celiac-related symptoms in individuals who have biopsy-confirmed celiac disease (CeD) and symptoms non-responsive to a gluten-free diet (GFD). Fifty participants, aged 18 to 75 years, who self-report persistent CeD-related symptoms despite taking a GFD for more than 1 year and who score \> 40 on the Celiac Symptom Index (CSI) will be randomized to receive L-tryptophan or placebo for 3 weeks.
Timeline
- Start
- 2022-12-01
- Primary completion
- 2025-04-01
- Completion
- 2025-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | amino acids | Unknown | 1000 mg | Oral |